Bettini and Rizzari recently responded with precision [1] to a letter our group sent to the European Journal of Internal Medicine regarding the possible benefits of administering the antidote glucarpidase outside the recommended time window in particular cases of methotrexate (MTX) intoxication where the prompt administration may not be feasible [2]. The contribution of the two authors to the debate on the topic is certainly worthy of interest considering the numerous questions raised, and the high knowledge of the authors about glucarpidase.
